Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLSDNASDAQ:KLTONASDAQ:NXTCNASDAQ:TELO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLSDClearside Biomedical$0.80-1.0%$0.83$0.70▼$1.65$62.17M2.06362,696 shs186,766 shsKLTOKlotho Neurosciences$1.60-20.0%$0.34$0.11▼$6.29$51.99M0.1821.50 million shs17.23 million shsNXTCNextCure$0.68+4.8%$0.44$0.22▼$1.82$18.23M1.07111,320 shs368,516 shsTELOTelomir Pharmaceuticals$1.96-2.0%$2.39$1.85▼$8.40$59.53M-0.38152,727 shs322,674 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLSDClearside Biomedical0.00%+1.72%-7.46%-10.08%-33.88%KLTOKlotho Neurosciences0.00%+680.49%+712.18%+464.57%+159,999,900.00%NXTCNextCure0.00%+37.49%+65.29%-1.15%-53.36%TELOTelomir Pharmaceuticals0.00%-8.84%-16.95%-57.21%-64.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLSDClearside Biomedical2.6166 of 5 stars3.55.00.00.03.40.00.0KLTOKlotho NeurosciencesN/AN/AN/AN/AN/AN/AN/AN/ANXTCNextCure4.6479 of 5 stars3.55.00.04.33.01.71.3TELOTelomir Pharmaceuticals2.0724 of 5 stars3.80.00.00.02.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLSDClearside Biomedical 3.00Buy$4.80500.00% UpsideKLTOKlotho Neurosciences 0.00N/AN/AN/ANXTCNextCure 3.00Buy$3.50413.95% UpsideTELOTelomir Pharmaceuticals 3.50Strong Buy$15.00665.31% UpsideCurrent Analyst Ratings BreakdownLatest NXTC, KLTO, CLSD, and TELO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025CLSDClearside BiomedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $5.005/16/2025CLSDClearside BiomedicalJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$5.00 ➝ $5.005/15/2025CLSDClearside BiomedicalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$4.00 ➝ $3.004/8/2025CLSDClearside BiomedicalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/31/2025CLSDClearside BiomedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/28/2025CLSDClearside BiomedicalChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/28/2025CLSDClearside BiomedicalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.003/17/2025NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLSDClearside Biomedical$3.76M16.52N/AN/A($0.25) per share-3.20KLTOKlotho NeurosciencesN/AN/A$1.68 per share0.95($2.16) per shareN/ANXTCNextCureN/AN/AN/AN/A$4.10 per shareN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/A$0.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLSDClearside Biomedical-$32.49M-$0.41N/AN/AN/A-413.83%N/A-92.90%8/11/2025 (Estimated)KLTOKlotho Neurosciences$1.35M-$0.36N/A∞N/AN/AN/A-25.89%N/ANXTCNextCure-$62.72M-$1.76N/AN/AN/AN/A-62.50%-53.67%7/30/2025 (Estimated)TELOTelomir Pharmaceuticals-$16.53M-$0.42N/AN/AN/AN/A-1,170.58%-832.67%8/12/2025 (Estimated)Latest NXTC, KLTO, CLSD, and TELO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025KLTOKlotho NeurosciencesN/A-$0.08N/A-$0.08N/AN/A5/14/2025Q1 2025CLSDClearside Biomedical-$0.12-$0.11+$0.01-$0.11$0.20 million$2.33 million5/12/2025Q1 2025TELOTelomir Pharmaceuticals-$0.10-$0.07+$0.03-$0.07N/AN/A5/1/2025Q1 2025NXTCNextCure-$0.40-$0.39+$0.01-$0.39N/AN/A3/31/2025Q4 2024KLTOKlotho NeurosciencesN/A-$0.07N/A-$0.07N/AN/A3/27/2025Q4 2024CLSDClearside Biomedical-$0.13-$0.10+$0.03-$0.10$0.27 million$0.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLSDClearside BiomedicalN/AN/AN/AN/AN/AKLTOKlotho NeurosciencesN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLSDClearside BiomedicalN/A4.494.49KLTOKlotho NeurosciencesN/A0.160.16NXTCNextCureN/A9.079.07TELOTelomir PharmaceuticalsN/A1.941.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLSDClearside Biomedical18.75%KLTOKlotho Neurosciences20.07%NXTCNextCure42.65%TELOTelomir PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCLSDClearside Biomedical6.20%KLTOKlotho Neurosciences26.70%NXTCNextCure17.90%TELOTelomir PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLSDClearside Biomedical3077.71 million68.87 millionOptionableKLTOKlotho NeurosciencesN/A32.49 million26.54 millionN/ANXTCNextCure9028.05 million24.28 millionOptionableTELOTelomir Pharmaceuticals129.76 millionN/AN/ANXTC, KLTO, CLSD, and TELO HeadlinesRecent News About These CompaniesTelomir Pharma’s Telomir-1 shows dose-dependent restoration of neurological, liver & kidney functions in preclinical for Wilson’s diseaseJune 14 at 11:03 AM | pharmabiz.comTELO Rises on Promising Telomir-1 Preclinical ResultsJune 13 at 3:50 PM | insidermonkey.comTELO Rises on Promising Telomir-1 Preclinical ResultsJune 13 at 3:34 PM | msn.comTELO Continues Trend of Significant Trial AnnouncementsJune 11, 2025 | msn.comTelomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease ModelJune 11, 2025 | accessnewswire.comTelomir Pharmaceuticals Announces Telomir-1 Resets the Body’s Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated ...June 7, 2025 | usatoday.comTELO Data Indicates Aging Reversal PotentialJune 6, 2025 | finance.yahoo.comTelomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner SyndromeJune 5, 2025 | accessnewswire.comTelomir announces positive preclinical data for its novel oral AMD therapeuticJune 3, 2025 | ophthalmologytimes.comTelomir Pharmaceuticals Joins BIO Convention for PartnershipsJune 2, 2025 | tipranks.comTelomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity PlatformJune 2, 2025 | accessnewswire.comTelomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration Animal Model Using FDA ...May 29, 2025 | finanznachrichten.deTELO Produces Results with Exciting AMD ImplicationsMay 29, 2025 | msn.comTelomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate EndpointsMay 29, 2025 | accessnewswire.comTelomir Pharmaceuticals CFO Michelle Yanez Leaves Company; Resignation Was a Mutual SeparationMay 21, 2025 | marketwatch.comTelomir Pharmaceuticals Appoints New Chief Financial OfficerMay 21, 2025 | tipranks.comTelomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease INDMay 21, 2025 | accessnewswire.comTelomir PharmaceuticalsMay 19, 2025 | thepharmaletter.comTelomir unveils new drug candidate against resistant bacteriaMay 16, 2025 | investing.comTelomir Pharma touts breakthrough in drug-resistant infectionsMay 16, 2025 | thepharmaletter.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNXTC, KLTO, CLSD, and TELO Company DescriptionsClearside Biomedical NASDAQ:CLSD$0.80 -0.01 (-0.98%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.80 0.00 (-0.38%) As of 06/13/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.Klotho Neurosciences NASDAQ:KLTO$1.60 -0.40 (-20.00%) As of 06/13/2025 04:00 PM EasternKlotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.NextCure NASDAQ:NXTC$0.68 +0.03 (+4.77%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.72 +0.03 (+4.99%) As of 06/13/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.Telomir Pharmaceuticals NASDAQ:TELO$1.96 -0.04 (-2.00%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.96 0.00 (-0.20%) As of 06/13/2025 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
